Perspective
Antibiotic-Resistant Bugs in the 21st Century — A Clinical Super-Challenge
N Engl J Med 2009; 360:439-443January 29, 2009
- Article
Slide Show
Antibiotic-Resistant Bugs.
In March 1942, a 33-year-old woman lay dying of streptococcal sepsis in a New Haven, Connecticut, hospital, and despite the best efforts of contemporary medical science, her doctors could not eradicate her bloodstream infection. Then they managed to obtain a small amount of a newly discovered substance called penicillin, which they cautiously injected into her. After repeated doses, her bloodstream was cleared of streptococci, she made a full recovery, and she went on to live to the age of 90.1 Sixty-six years after her startling recovery, a report2 described a 70-year-old man in San Francisco with endocarditis caused by vancomycin-resistant Enterococcus faecium (VRE). Despite the administration, for many days, of the best antibiotics available for combating VRE, physicians were unable to sterilize the patient's blood, and he died still bacteremic. We have come almost full circle and arrived at a point as frightening as the preantibiotic era: for patients infected with multidrug-resistant bacteria, there is no magic bullet.
It is difficult to imagine undertaking today's surgical procedures, transplantations, cancer chemotherapy, or care of the critically ill or HIV-infected without effective antimicrobial agents. Bacteria are champions of evolution, and a few microbes have adapted to a point where they pose serious clinical challenges for humans. Among the gram-positive organisms, methicillin-resistant Staphylococcus aureus (MRSA) and E. faecium represent the biggest therapeutic hurdles (see table
Multidrug-Resistant Bacterial Organisms Causing Major Clinical Problems. and slide presentation). The evolution of MRSA exemplifies the genetic adaptation of an organism into a first-class multidrug-resistant pathogen. After the introduction of penicillin and, later, methicillin, S. aureus quickly developed resistance to these β-lactam compounds, and by 2003, more than 50% of S. aureus isolates recovered in U.S. hospitals were MRSA.Then MRSA began developing resistance to glycopeptides, first evolving, through largely undefined mutations, low-level resistance to vancomycin, which was associated with a thickening of the pathogen's cell walls. Such isolates were designated VISA (or GISA), for vancomycin (or glycopeptide) intermediately resistant S. aureus (see diagram
Common Mechanisms of Resistance in Methicillin-Resistant Staphylococccus aureus.). VISA is difficult for clinical laboratories to detect, but its presence is associated with the therapeutic failure of glycopeptides. The breakpoints for susceptibility to vancomycin have therefore been changed, screening tests for VISA have been proposed, and much debate has ensued regarding the usefulness of vancomycin in the treatment of serious MRSA infections.Next, strains of MRSA with true, high-level resistance to vancomycin (vancomycin-resistant S. aureus, or VRSA) emerged. Such resistance is due to the acquisition of the vanA gene cluster, originally described in enterococci. Fortunately, fewer than a dozen such isolates have been reported (mostly in Michigan), and their dissemination appears to be limited, at least for now. VRSA, like other strains of health care–associated MRSA, is often resistant to multiple drugs, including clindamycin, aminoglycosides, trimethoprim–sulfamethoxazole, rifampin, and fluoroquinolones.
MRSA has also recently emerged as an important cause of infections outside hospitals. Community-associated MRSA is now the leading cause of identifiable skin and soft-tissue infections seen in U.S. emergency rooms. Such MRSA frequently causes severe infections resembling spider bites, as well as severe necrotizing fasciitis and pneumonia, and it often produces toxins such as the Panton–Valentine leukocidin and cytolytic peptides. It has also acquired genes that may increase its ability to survive. A single clone, USA300, is responsible for most community-associated MRSA infections in the United States.3 Although such MRSA is commonly susceptible to oral antibiotics such as clindamycin, fluoroquinolones, trimethoprim–sulfamethoxazole, tetracyclines, and rifampin, some multidrug-resistant strains are emerging.
Though less virulent than MRSA, enterococci have long represented therapeutic problems, initially because of their “tolerance” to penicillin and vancomycin (which inhibit but don't kill them). Enterococci are the third most common cause of infective endocarditis, and the effect of penicillin tolerance on therapeutic outcomes was apparent by the late 1940s, when it became routine to add an aminoglycoside to penicillin in treating this disease. High-level resistance to all aminoglycosides is increasing, however, so that the synergistic and bactericidal activity of the combination of a cell-wall agent and an aminoglycoside is no longer effective against some isolates of enterococci from endocarditis.
More worrisome is the increased occurrence of E. faecium infections, since the majority of E. faecium isolated in U.S. critical care units is now resistant to vancomycin (more than 90% of VRE isolates in the United States are E. faecium) and to ampicillin (almost 100% of isolates are resistant), with some strains having developed resistance to the newer antibiotics as well. No appropriate therapy for VRE endocarditis has been defined,4 and no agent has been approved by the Food and Drug Administration for this indication. The emergence of multidrug-resistant E. faecium correlates with the predominance of a single genetic lineage worldwide; members of this lineage have acquired genetic determinants that appear to increase their success in the hospital environment, and some have developed resistance to practically all available antibiotics.
Despite the recent dramatic reduction in antibiotic research by pharmaceutical companies, several compounds have been developed or resurrected to treat gram-positive infections. However, the available agents have important limitations: none have been shown to work better than vancomycin against MRSA; quinupristin–dalfopristin and linezolid have important toxic effects, and resistance to each has been observed (including linezolid-resistant VRE in patients who have never received the drug); daptomycin has sometimes failed against MRSA and enterococci, and resistance to it has emerged; and there are few data regarding tigecycline for enterococcal infections, and its low blood levels raise concern about its use in bacteremia. Among the agents in late stages of clinical development, the new cephalosporins (ceftobiprole and ceftaroline) will not be clinically useful against ampicillin-resistant E. faecium; dalbavancin, telavancin, and oritavancin will have important limitations for the treatment of vancomycin-resistant organisms; and although iclaprim may have a role in MRSA infections, its clinical usefulness against enterococci has not been demonstrated.
The situation is even more dire when it comes to nosocomial gram-negative infections, since no new antibiotics against these multidrug-resistant organisms are in advanced stages of clinical development. Though multidrug-resistant Pseudomonas aeruginosa and acinetobacter are the best-known therapeutic challenges among the gram-negative bacteria (e.g., multidrug-resistant acinetobacter species are causing enormous challenges in soldiers returning from Iraq and Afghanistan), resistance to the most potent antibiotics has recently extended to members of the Enterobacteriaceae family, including hospital-associated strains of klebsiella, Escherichia coli, and enterobacter. Equally worrisome is the fact that multidrug-resistant gram-negative organisms have been found in otherwise healthy patients outside of hospitals — for instance, urinary tract infections caused by E. coli that is resistant to trimethoprim–sulfamethoxazole, fluoroquinolones, or both and that produce extended-spectrum β-lactamases (enzymes capable of destroying the most potent cephalosporins),5 and recent major outbreaks of food poisoning caused by multidrug-resistant salmonella.
Until recently, carbapenems, such as imipenem, were almost uniformly active against resistant gram-negative organisms, but some strains have now developed very effective ways to deal with the carbapenems, including the production of β-lactamases (designated carbapenemases) that demolish the carbapenems; changes in outer-membrane porins that block the entry of these antibiotics; and active pumping of the antibiotic out of the cell using complex “efflux pumps.” The situation is further complicated by the fact that the “permeability” barrier and efflux mechanisms also affect other classes of antibiotics (e.g., quinolones, aminoglycosides, and tigecycline). Moreover, the common presence of these β-lactamase genes of gram-negative bacteria in transferable mobile elements means that these genes could reach virtually any gram-negative bacterium and become a major threat in the future. Recognition of the presence of a carbapenemase in a gram-negative organism is of paramount importance, since strict infection-control measures are required to avert hospital epidemics and the dissemination of these genes to other gram-negative species.
Faced with this gloomy picture, 21st-century clinicians must turn to compounds developed decades ago and previously abandoned because of toxicity — or test everything they can think of and use whatever looks active. The resurrected polymixins (e.g., colistin with or without rifampin) are often the only available alternative for some pan-resistant gram-negatives, particularly acinetobacter, although toxicity (mainly renal) is still a problem, and reports of resistance are emerging.
It is more difficult than ever to eradicate infections caused by antibiotic-resistant “superbugs,” and the problem is exacerbated by a dry pipeline for new antimicrobials with bactericidal activity against gram-negative bacteria and enterococci. A concerted effort on the part of academic researchers and their institutions, industry, and government is crucial if humans are to maintain the upper hand in this battle against bacteria — a fight with global consequences.
Dr. Arias reports receiving a lecture fee from Merck and grant support from Pfizer. Dr. Murray reports receiving grant support from Johnson & Johnson, Astellas, and Intercell and serving as a consultant for Astellas Pharma and Theravance, Cubist, Targanta Therapeutics, Johnson & Johnson, Pfizer, AstraZeneca, and Wyeth-Ayerst. No other potential conflict of interest relevant to this article was reported.
Source Information
Dr. Arias is an assistant professor of medicine at the University of Texas Medical School, Houston, and director of the Molecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogotá, Colombia. Dr. Murray is a professor and the vice-chair for research in the Department of Internal Medicine and the director of the Division of Infectious Diseases, University of Texas Medical School, Houston.
- References
References
1
Lax E. The mold on Dr. Florey's coat: the story of the penicillin miracle. New York: Henry Holt, 2004.
2
Schwartz BS ,Ngo PD ,Guglielmo BJ . Daptomycin treatment failure for vancomycin-resistant Enterococcus faecium infective endocarditis: impact of protein binding? Ann Pharmacother 2008;42:289-290
CrossRef | Web of Science | Medline3
Diep BA ,Gill SR ,Chang RF , et al. Complete genome sequence of USA300, an epidemic clone of community-acquired methicillin-resistant Staphylococcus aureus. Lancet 2006;367:731-739
CrossRef | Web of Science | Medline4
Arias CA ,Murray BE . Emergence and management of drug-resistant enterococcal infections. Expert Rev Anti Infect Ther 2008;6:637-655
CrossRef | Web of Science | Medline5
Pitout JD ,Laupland KB . Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008;8:159-166
CrossRef | Web of Science | Medline
- Citing Articles (83)
Citing Articles
1
Melanie Jünger, Wolfgang Vautz, Martin Kuhns, Lena Hofmann, Siobhán Ulbricht, Jörg Ingo Baumbach, Michael Quintel, Thorsten Perl. (2012) Ion mobility spectrometry for microbial volatile organic compounds: a new identification tool for human pathogenic bacteria. Applied Microbiology and Biotechnology
CrossRef2
G. Pongas, G. Hamilos, K. V. Rolston, Dimitrios P. Kontoyiannis. (2012) Formal adult infectious disease specialist consultations in the outpatient setting at a comprehensive cancer center (1998–2008): Diverse and impactful. Supportive Care in Cancer 20:2, 261-265
CrossRef3
Damion K. Corrigan, Holger Schulze, Grace Henihan, Ilenia Ciani, Gerard Giraud, Jonathan G. Terry, Anthony J. Walton, Ronald Pethig, Peter Ghazal, Jason Crain, Colin J. Campbell, Andrew R. Mount, Till T. Bachmann. (2012) Impedimetric detection of single-stranded PCR products derived from methicillin resistant Staphylococcus aureus (MRSA) isolates.. Biosensors and Bioelectronics
CrossRef4
Marin H. Kollef. (2012) Prevention of ventilator-associated pneumonia or ventilator-associated complications. Critical Care Medicine 40:1, 271-277
CrossRef5
Gerard D. Wright. (2012) Antibiotics: A New Hope. Chemistry & Biology 19:1, 3-10
CrossRef6
Brandon Findlay, George G. Zhanel, Frank Schweizer. (2012) Neomycin–phenolic conjugates: Polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding. Bioorganic & Medicinal Chemistry Letters
CrossRef7
Shu Li, Jian Jia, Xiaoguang Gao, Xiuli He, Jianping Li. (2012) Analysis of antibiotics from liquid sample using electrospray ionization-ion mobility spectrometry. Analytica Chimica Acta
CrossRef8
Aurélien Dinh, Jérôme Salomon, Jean Pierre Bru, Louis Bernard. (2011) Fosfomycin: Efficacy against infections caused by multidrug-resistant bacteria. Scandinavian Journal of Infectious Diseases1-8
CrossRef9
E. L. Flannery, L. Wang, S. Zollner, B. Foxman, H. L. T. Mobley, L. Mody. (2011) Wounds, Functional Disability, and Indwelling Devices Are Associated With Cocolonization by Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci in Southeast Michigan. Clinical Infectious Diseases 53:12, 1215-1222
CrossRef10
A. Kropec, I. G. Sava, C. Vonend, T. Sakinc, E. Grohmann, J. Huebner. (2011) Identification of SagA as a novel vaccine target for the prevention of Enterococcus faecium infections. Microbiology 157:12, 3429-3434
CrossRef11
A.S. Kakatkar, L.S. Pansare, R.K. Gautam, R. Shashidhar, M. Karani, J.R. Bandekar. (2011) Molecular characterization of antibiotic resistant Salmonella isolates from Indian foods. Food Research International 44:10, 3272-3275
CrossRef12
Jan Borysowski, Małgorzata Łobocka, Ryszard Międzybrodzki, Beata Weber-Dabrowska, Andrzej Górski. (2011) Potential of Bacteriophages and Their Lysins in the Treatment of MRSA. BioDrugs 25:6, 347-355
CrossRef13
Christian M. Gampe, Hirokazu Tsukamoto, Tsung-Shing Andrew Wang, Suzanne Walker, Daniel Kahne. (2011) Modular synthesis of diphospholipid oligosaccharide fragments of the bacterial cell wall and their use to study the mechanism of moenomycin and other antibiotics. Tetrahedron 67:51, 9771-9778
CrossRef14
Carlos López-Abarrategui, Annia Alba, Osmar N. Silva, Osvaldo Reyes-Acosta, Ilka M. Vasconcelos, Jose T.A. Oliveira, Ludovico Migliolo, Maysa P. Costa, Carolina R. Costa, Maria R.R. Silva, Hilda E. Garay, Simoni C. Dias, Octávio L. Franco, Anselmo J. Otero-González. (2011) Functional characterization of a synthetic hydrophilic antifungal peptide derived from the marine snail Cenchritis muricatus. Biochimie
CrossRef15
Esther Heikens, Kavindra V. Singh, Karen D. Jacques-Palaz, Miranda van Luit-Asbroek, Evelien A.N. Oostdijk, Marc J.M. Bonten, Barbara E. Murray, Rob J.L. Willems. (2011) Contribution of the enterococcal surface protein Esp to pathogenesis of Enterococcus faecium endocarditis. Microbes and Infection 13:14-15, 1185-1190
CrossRef16
Matthew B. Dickerson, Caitlin L. Knight, Maneesh K. Gupta, Heather R. Luckarift, Lawrence F. Drummy, Michael L. Jespersen, Glenn R. Johnson, Rajesh R. Naik. (2011) Hybrid fibers containing protein-templated nanomaterials and biologically active components as antibacterial materials. Materials Science and Engineering: C 31:8, 1748-1758
CrossRef17
S. I. Chernysh, N. A. Gordja. (2011) The immune system of maggots of the blow fly (Calliphora vicina) as a source of medicinal drugs. Journal of Evolutionary Biochemistry and Physiology 47:6, 524-533
CrossRef18
Yi Cheng, Chen-Yu Tsao, Hsuan-Chen Wu, Xiaolong Luo, Jessica L. Terrell, Jordan Betz, Gregory F. Payne, William E. Bentley, Gary W. Rubloff. (2011) Electroaddressing Functionalized Polysaccharides as Model Biofilms for Interrogating Cell Signaling. Advanced Functional Materialsn/a-n/a
CrossRef19
M. H. Kollef, S. T. Micek. (2011) Patients Hospitalized With Pneumonia: Determining the Need for Broad-Spectrum Antibiotic Therapy. Clinical Infectious Diseases
CrossRef20
A. Simon, E. Müllenborn, M. Prelog, W. Schenk, J. Holzapfel, F. Ebinger, A. Klabunde-Cherwon, J. Faber, A. H. Groll, K. Masjosthusmann, C. Dohna-Schwake, K. Beutel, E. Dirkwinkel, T. Lehrnbecher, R. A. Ammann, A. Müller. (2011) Use of linezolid in neonatal and pediatric inpatient facilities—results of a retrospective multicenter survey. European Journal of Clinical Microbiology & Infectious Diseases
CrossRef21
Lucy Brown Palmer. (2011) Battle cry in the intensive care unit: Are we listening?*. Critical Care Medicine 39:11, 2568-2570
CrossRef22
Scott T. Micek, Richard M. Reichley, Marin H. Kollef. (2011) Health Care-Associated Pneumonia (HCAP). Medicine 90:6, 390-395
CrossRef23
Lindsay Kalan, Gerard D. Wright. (2011) Antibiotic adjuvants: multicomponent anti-infective strategies. Expert Reviews in Molecular Medicine 13,
CrossRef24
Daniela Jabes. (2011) The antibiotic R&D pipeline: an update. Current Opinion in Microbiology 14:5, 564-569
CrossRef25
Monthida Fangtham, Alan N. Baer. (2011) Methicillin-Resistant Staphylococcus aureus Arthritis in Adults: Case Report and Review of the Literature. Seminars in Arthritis and Rheumatism
CrossRef26
M. H. Kollef, Y. Golan, S. T. Micek, A. F. Shorr, M. I. Restrepo. (2011) Appraising Contemporary Strategies to Combat Multidrug Resistant Gram-Negative Bacterial Infections-Proceedings and Data From the Gram-Negative Resistance Summit. Clinical Infectious Diseases 53:suppl 2, S33-S55
CrossRef27
Lucy B. Palmer. (2011) Aerosolized Antibiotics in the Intensive Care Unit. Clinics in Chest Medicine 32:3, 559-574
CrossRef28
Scott T. Micek, Emily C. Welch, Junaid Khan, Mubashir Pervez, Joshua A. Doherty, Richard M. Reichley, Joan Hoppe-Bauer, W. Michael Dunne, Marin H. Kollef. (2011) Resistance to empiric antimicrobial treatment predicts outcome in severe sepsis associated with gram-negative bacteremia. Journal of Hospital Medicine 6:7, 405-410
CrossRef29
Ben Burrowes, David R Harper, Joseph Anderson, Malcolm McConville, Mark C Enright. (2011) Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens. Expert Review of Anti-infective Therapy 9:9, 775-785
CrossRef30
Manjeshwar Shrinath Baliga, Ramakrishna J. Pai, Harshith P. Bhat, Princy Louis Palatty, Rekha Boloor. (2011) Chemistry and medicinal properties of the Bakul (Mimusops elengi Linn): A review. Food Research International 44:7, 1823-1829
CrossRef31
Marin H. Kollef. (2011) Hospital-acquired pneumonia/ventilator-associated pneumonia prevention: Truth or dare!*. Critical Care Medicine 39:8, 2015-2016
CrossRef32
Michael T. Johnson, Richard Reichley, Joan Hoppe-Bauer, W. Michael Dunne, Scott Micek, Marin Kollef. (2011) Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis*. Critical Care Medicine 39:8, 1859-1865
CrossRef33
Andrea Marra. (2011) Antibacterial resistance: is there a way out of the woods?. Future Microbiology 6:7, 707-709
CrossRef34
P. McClean, C. Hughes, M. Tunney, H. Goossens, B. Jans, , B. Jans, R. Stroobants, H. Goossens, A. Budimir, A. Tambic, K. Rudolf, J. Vleck, C. S. Jensen, L. Fleet, M. Haapasaari, A. Huuskonen, M. Kanerva, T. Karki, L. Lauritsalo, O. Lyytikainen, M. Matsinen, M. Rummukainen, T. Tiitinen, G. Gavazzi, N. Wischnewski, B. Karolina, G. Ternak, R. Cunney, D. Mitchell, M. L. Moro, F. Greta, U. Dumpis, A. Judeiks, P. Zarb, A. Haenen, B. van Benthem, S. Natsch, M.-J. Veldman, C. Hughes, P. McClean, H. S. Blix, H. M. Eriksen, A. R. Saether, W. Hryniewicz, B. Mazinska, S. Ratchina, P. Davey, A. Mullings, T. L. Zupanc, L. Karvestedt. (2011) Antimicrobial prescribing in European nursing homes. Journal of Antimicrobial Chemotherapy 66:7, 1609-1616
CrossRef35
Varnika Roy, Bryn L. Adams, William E. Bentley. (2011) Developing next generation antimicrobials by intercepting AI-2 mediated quorum sensing. Enzyme and Microbial Technology 49:2, 113-123
CrossRef36
Holger Heuer, Heike Schmitt, Kornelia Smalla. (2011) Antibiotic resistance gene spread due to manure application on agricultural fields. Current Opinion in Microbiology 14:3, 236-243
CrossRef37
Josep Rayo, Neri Amara, Pnina Krief, Michael M. Meijler. (2011) Live Cell Labeling of Native Intracellular Bacterial Receptors Using Aniline-Catalyzed Oxime Ligation. Journal of the American Chemical Society 133:19, 7469-7475
CrossRef38
Donald P Levine, Odaliz Abreu Lanfranco. (2011) MRSA guidelines: a matter of time. Expert Review of Anti-infective Therapy 9:5, 495-496
CrossRef39
Tim Maisch, Steffen Hackbarth, Johannes Regensburger, Ariane Felgenträger, Wolfgang Bäumler, Michael Landthaler, Beate Röder. (2011) Photodynamic inactivation of multi-resistant bacteria (PIB) - a new approach to treat superficial infections in the 21st century. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 9:5, 360-366
CrossRef40
Azusa Kato, Haruhisa Hirata, Yoshitami Ohashi, Kiyonaga Fujii, Kenji Mori, Ken-ichi Harada. (2011) A new anti-MRSA antibiotic complex, WAP-8294A II. Structure characterization of minor components by ESI LCMS and MS/MS. The Journal of Antibiotics 64:5, 373-379
CrossRef41
T. Choudhury, K. V. Singh, J. Sillanpaa, S. R. Nallapareddy, B. E. Murray. (2011) Importance of Two Enterococcus faecium Loci Encoding Gls-like Proteins for In Vitro Bile Salts Stress Response and Virulence. Journal of Infectious Diseases 203:8, 1147-1154
CrossRef42
Sharon L. Achilles, Matthew F. Reeves. (2011) Prevention of infection after induced abortion. Contraception 83:4, 295-309
CrossRef43
Debmalya Barh, Sandeep Tiwari, Neha Jain, Amjad Ali, Anderson Rodrigues Santos, Amarendra Narayan Misra, Vasco Azevedo, Anil Kumar. (2011) In silico subtractive genomics for target identification in human bacterial pathogens. Drug Development Research 72:2, 162-177
CrossRef44
Daryl J. Hoban, George G. Zhanel. (2011) Introduction to the CANWARD Study (2007–2009). Diagnostic Microbiology and Infectious Disease 69:3, 289-290
CrossRef45
Elif Sahin Horasan, Gulden Ersoz, Mehmet Horoz, Musa Göksu, Sevim Karacorlu, Ali Kaya. (2011) Risk factors for infections caused by multidrug-resistant bacteria in patients with solid tumours. Scandinavian Journal of Infectious Diseases 43:2, 107-111
CrossRef46
William C. Wimley, Kalina Hristova. (2011) Antimicrobial Peptides: Successes, Challenges and Unanswered Questions. The Journal of Membrane Biology 239:1-2, 27-34
CrossRef47
Frederick Harris, Lynne Pierpoint. (2011) Photodynamic therapy based on 5-aminolevulinic acid and its use as an antimicrobial agent. Medicinal Research Reviewsn/a-n/a
CrossRef48
Guido Werner, Carola Fleige, Uta Geringer, Willem van Schaik, Ingo Klare, Wolfgang Witte. (2011) IS element IS16 as a molecular screening tool to identify hospital-associated strains of Enterococcus faecium. BMC Infectious Diseases 11:1, 80
CrossRef49
Danielle H. Dube, Kanokwan Champasa, Bo Wang. (2011) Chemical tools to discover and target bacterial glycoproteins. Chemical Communications 47:1, 87
CrossRef50
Dukki Han, Tatsuya Unno, Jeonghwan Jang, Kyungtaek Lim, Sun-Nim Lee, GwangPyo Ko, Michael J. Sadowsky, Hor-Gil Hur. (2011) The occurrence of virulence traits among high-level aminoglycosides resistant Enterococcus isolates obtained from feces of humans, animals, and birds in South Korea. International Journal of Food Microbiology 144:3, 387-392
CrossRef51
Hsiu-Chien Chan, Yu-Ting Huang, Syue-Yi Lyu, Chuen-Jiuan Huang, Yi-Shan Li, Yu-Chen Liu, Chia-Cheng Chou, Ming-Daw Tsai, Tsung-Lin Li. (2011) Regioselective deacetylation based on teicoplanin-complexed Orf2* crystal structures. Molecular BioSystems 7:4, 1224
CrossRef52
Hui-Min Wang, Chung-Yi Chen, Hsi-An Chen, Wan-Chun Huang, Wei-Ru Lin, Tun-Chieh Chen, Chun-Yu Lin, Hsin-Ju Chien, Po-Liang Lu, Chiu-Mei Lin, Yen-Hsu Chen. (2010) Zingiber officinale (ginger) compounds have tetracycline-resistance modifying effects against clinical extensively drug-resistant Acinetobacter baumannii. Phytotherapy Research 24:12, 1825-1830
CrossRef53
Martti Vaara, Timo Vaara. (2010) Structure–activity studies on novel polymyxin derivatives that carry only three positive charges. Peptides 31:12, 2318-2321
CrossRef54
Kesselheim, Aaron S., . (2010) Using Market-Exclusivity Incentives to Promote Pharmaceutical Innovation. New England Journal of Medicine 363:19, 1855-1862
Full Text55
Sławomir Letkiewicz, Ryszard Międzybrodzki, Marlena Kłak, Ewa Jończyk, Beata Weber-Dąbrowska, Andrzej Górski. (2010) The perspectives of the application of phage therapy in chronic bacterial prostatitis. FEMS Immunology & Medical Microbiology 60:2, 99-112
CrossRef56
Ángel Hernández-Merino. (2010) Uso prudente de antibióticos: propuestas de mejora desde la pediatría comunitaria. Enfermedades Infecciosas y Microbiología Clínica 28, 23-27
CrossRef57
Martti Vaara. (2010) Polymyxins and their novel derivatives. Current Opinion in Microbiology 13:5, 574-581
CrossRef58
Henrik Stender. (2010) AntibioDx. Expert Review of Molecular Diagnostics 10:7, 841-843
CrossRef59
I. G. Sava, E. Heikens, A. Kropec, C. Theilacker, R. Willems, J. Huebner. (2010) Enterococcal surface protein contributes to persistence in the host but is not a target of opsonic and protective antibodies in Enterococcus faecium infection. Journal of Medical Microbiology 59:9, 1001-1004
CrossRef60
Abugafar M.L. Hossion, Nao Otsuka, Rafiya K. Kandahary, Tomofusa Tsuchiya, Wakano Ogawa, Akimasa Iwado, Yoshito Zamami, Kenji Sasaki. (2010) Design, synthesis, and biological evaluation of a novel series of quercetin diacylglucosides as potent anti-MRSA and anti-VRE agents. Bioorganic & Medicinal Chemistry Letters 20:17, 5349-5352
CrossRef61
Stefano Donadio, Sonia Maffioli, Paolo Monciardini, Margherita Sosio, Daniela Jabes. (2010) Antibiotic discovery in the twenty-first century: current trends and future perspectives. The Journal of Antibiotics 63:8, 423-430
CrossRef62
Gianfranco De Pascale, Gerard D. Wright. (2010) Antibiotic Resistance by Enzyme Inactivation: From Mechanisms to Solutions. ChemBioChem 11:10, 1325-1334
CrossRef63
Herman O Sintim, Jacqueline AI Smith, Jingxin Wang, Shizuka Nakayama, Lei Yan. (2010) Paradigm shift in discovering next-generation anti-infective agents: targeting quorum sensing, c-di-GMP signaling and biofilm formation in bacteria with small molecules. Future Medicinal Chemistry 2:6, 1005-1035
CrossRef64
Mark C. Grier, Lynne K. Garrity-Ryan, Victoria J. Bartlett, Kevin A. Klausner, Peter J. Donovan, Caroline Dudley, Michael N. Alekshun, S. Ken Tanaka, Michael P. Draper, Stuart B. Levy, Oak K. Kim. (2010) N-Hydroxybenzimidazole inhibitors of ExsA MAR transcription factor in Pseudomonas aeruginosa: In vitro anti-virulence activity and metabolic stability. Bioorganic & Medicinal Chemistry Letters 20:11, 3380-3383
CrossRef65
M. Vaara, O. Siikanen, J. Apajalahti, N. Frimodt-Moller, T. Vaara. (2010) Susceptibility of carbapenemase-producing strains of Klebsiella pneumoniae and Escherichia coli to the direct antibacterial activity of NAB739 and to the synergistic activity of NAB7061 with rifampicin and clarithromycin. Journal of Antimicrobial Chemotherapy 65:5, 942-945
CrossRef66
Matthew E. Falagas, Sofia Maraki, Drosos E. Karageorgopoulos, Antonia C. Kastoris, Anastasios Kapaskelis, George Samonis. (2010) Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin. International Journal of Antimicrobial Agents 35:5, 497-499
CrossRef67
D. S. Kim, K. V. Singh, S. R. Nallapareddy, X. Qin, D. Panesso, C. A. Arias, B. E. Murray. (2010) The fms21 (pilA)-fms20 locus encoding one of four distinct pili of Enterococcus faecium is harboured on a large transferable plasmid associated with gut colonization and virulence. Journal of Medical Microbiology 59:4, 505-507
CrossRef68
Yi-Wei Tang, Charles W. Stratton. (2010) Staphylococcus aureus: An Old Pathogen with New Weapons. Clinics in Laboratory Medicine 30:1, 179-208
CrossRef69
Kalyankumar Marikallappa Matti, Chandrashekhar Jagadeeshshastri Savanurmath, Shivayogeppa Bangareppa Hinchigeri. (2010) A Promising Broad Spectrum Antimicrobial Red Fluorescent Protein Present in Silkworm Excreta. Biological & Pharmaceutical Bulletin 33:7, 1143-1147
CrossRef70
Y.-H. Chen, C.-Y. Liu, J.-J. Lu, C.-H. R. King, P.-R. Hsueh. (2009) In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan. Journal of Antimicrobial Chemotherapy 64:6, 1226-1229
CrossRef71
Ulrich Sonnenborn, Jürgen Schulze. (2009) The non-pathogenic Escherichia coli strain Nissle 1917 – features of a versatile probiotic. Microbial Ecology in Health and Disease 21:3-4, 122-158
CrossRef72
Ryszard Międzybrodzki, Wojciech Fortuna, Beata Weber-Dąbrowska, Andrzej Górski. (2009) A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. Clinical and Experimental Medicine 9:4, 303-312
CrossRef73
Ausaf F. Mohammad, Nicky Ambrose, Ole-Petter R. Hamnvik, Grainne Kearns. (2009) Meticillin-sensitive Staphylococcus aureus costochondritis in a healthy man. Nature Reviews Rheumatology 5:12, 708-710
CrossRef74
Eliahu Bishburg, Kathryn Bishburg. (2009) Minocycline—an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. International Journal of Antimicrobial Agents 34:5, 395-401
CrossRef75
Lucy B Palmer. (2009) Aerosolized antibiotics in critically ill ventilated patients. Current Opinion in Critical Care 15:5, 413-418
CrossRef76
S. Nseir, G. Grailles, A. Soury-Lavergne, F. Minacori, I. Alves, A. Durocher. (2009) Accuracy of American Thoracic Society/Infectious Diseases Society of America criteria in predicting infection or colonization with multidrug-resistant bacteria at intensive-care unit admission. Clinical Microbiology and Infection
CrossRef77
Giovanni Montini, Ian Hewitt. (2009) Urinary tract infections: to prophylaxis or not to prophylaxis?. Pediatric Nephrology 24:9, 1605-1609
CrossRef78
Antoni P.A. Hendrickx, Rob J.L. Willems, Marc J.M. Bonten, Willem van Schaik. (2009) LPxTG surface proteins of enterococci. Trends in Microbiology 17:9, 423-430
CrossRef79
S. Letkiewicz, R. Międzybrodzki, W. Fortuna, B. Weber-Dąbrowska, A. Górski. (2009) Eradication of Enterococcus faecalis by phage therapy in chronic bacterial prostatitis — case report. Folia Microbiologica 54:5, 457-461
CrossRef80
Daniel D Long, Daniel G Marquess. (2009) Novel heterodimer antibiotics: a review of recent patent literature. Future Medicinal Chemistry 1:6, 1037-1050
CrossRef81
Ursula Theuretzbacher. (2009) Future antibiotics scenarios: is the tide starting to turn?. International Journal of Antimicrobial Agents 34:1, 15-20
CrossRef82
Mohan Venkatesh, Steven Abrams. (2009) Can lactoferrin prevent neonatal sepsis and necrotizing enterocolitis?. Expert Review of Anti-infective Therapy 7:5, 515-525
CrossRef83
Chester A. Faunce, Henrich H. Paradies. (2009) Two new colloidal crystal phases of lipid A-monophosphate: Order-to-order transition in colloidal crystals. The Journal of Chemical Physics 131:24, 244708
CrossRef
